{"id":"W4402354861","doi":"10.3310/jwtr4127","title":"Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT","year":2024,"lang":"en","type":"article","venue":"Health Technology Assessment","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"Programme Grants for Applied Research; Health Technology Assessment Programme; British Society of Interventional radiology; International Network of Agencies for Health Technology Assessment; Ipsen; European School of Oncology; Department of Health and Social Care; University of Leeds; National Institute for Health and Care Research; Bowel Cancer UK; British Heart Foundation; Engineering and Physical Sciences Research Council; AstraZeneca; National Cancer Research Institute; Cancer Research UK; Boston Scientific Corporation; GlaxoSmithKline; Amgen","keywords":"Medicine; Internal medicine; Sunitinib; Randomized controlled trial; Quality of life (healthcare); Confidence interval; Pazopanib; Intention-to-treat analysis; Renal cell carcinoma; Oncology; Surgery","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002901476,0.0002699833,0.0005591626,0.000282893,0.0001683735,0.00001706271,0.00007618345,0.0001264522,0.00001214609],"category_scores_gemma":[0.000006730975,0.0001455954,0.00006662328,0.0005289443,0.0002045492,0.00007727763,0.00002159098,0.0002231436,0.000001071293],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001385498,"about_ca_system_score_gemma":0.001908437,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001481066,"about_ca_topic_score_gemma":0.001189223,"domain_scores_codex":[0.998342,0.00005538743,0.0004977058,0.0004467652,0.0003338808,0.0003243108],"domain_scores_gemma":[0.9988175,0.00009958557,0.0003124083,0.0004406388,0.0002363035,0.00009357315],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01199909,0.003792006,0.702665,0.0069127,0.002505749,0.0004037715,0.003684781,0.0004764122,0.009934662,0.004793816,0.004122973,0.248709],"study_design_scores_gemma":[0.0387903,0.08648023,0.6198488,0.01251295,0.002029589,0.0003624474,0.008481367,0.02323515,0.1861729,0.0004432764,0.02062779,0.001015144],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.962391,0.003583079,0.0028887,0.02612011,0.0001278478,0.004491899,0.0001093558,0.0002065849,0.00008146348],"genre_scores_gemma":[0.9925012,0.0003982059,0.004586451,0.0001052478,0.00007637711,0.001938747,0.0002830243,0.00003544038,0.00007531032],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2476939,"threshold_uncertainty_score":0.5937209,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02563838062294782,"score_gpt":0.3444084198598867,"score_spread":0.3187700392369389,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}